Daré Bioscience Announces Corporate Presentation for Investors

Daré Bioscience ( (DARE) ) has issued an announcement.

On June 9, 2025, Daré Bioscience, Inc. announced its intention to use a corporate presentation in meetings with securities market participants and others. The presentation will be accessible on the company’s website in the ‘Investors’ section. This move is part of Daré’s strategy to engage with stakeholders and provide transparency about its operations and future plans.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Spark’s Take on DARE Stock

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

Daré Bioscience’s overall stock score reflects significant financial challenges, including insolvency risk and negative equity. While strategic initiatives and cost management are positive, ongoing financial distress and regulatory challenges weigh heavily on the score. Technical indicators and valuation raise additional concerns, limiting the stock’s attractiveness.

To see Spark’s full report on DARE stock, click here.

More about Daré Bioscience

Average Trading Volume: 19,692

Technical Sentiment Signal: Sell

Current Market Cap: $28.32M

Learn more about DARE stock on TipRanks’ Stock Analysis page.